Ovid Therapeutics Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Ovid Therapeutics Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 383% in 3 years; of every extra $100 of sales, $639 became extra profit. Higher than 95% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 2 of the last 3 years; profit grew in 3 of 3. Steadier than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 3/3Sales grew in 2 of the last 3 years; profit grew in 3 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$639Sales grew 383% in 3 years; of every extra $100 of sales, $639 became extra profit.
Higher than 95% of Healthcare companies in United States.
Asset Productivity Ratio
+383% / -3%In 3 years sales changed by +383% while total assets changed by -3%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-26.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 62% of Healthcare companies in United States.
Cash Cushion Ratio
+12%Cash, after subtracting all debt, equals 12% of its market value (net cash).
Higher than 53% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Ovid Therapeutics Inc. made a loss over the last year. Ovid Therapeutics Inc. owes $0.10 for every $1 it owns. Ovid Therapeutics Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossOvid Therapeutics Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.21The share price is 2.21 times Ovid Therapeutics Inc.'s book value per share, lower than 54% of Healthcare companies in United States.
Market cap
$463 MThe total market value of all of Ovid Therapeutics Inc.'s shares at today's price (share price × number of shares), larger than 53% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$210 MWhat Ovid Therapeutics Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.07Net worth divided by the number of shares. The share price of $2.37 is 2.2 times this, which is the P/B above.
Return on equity (ROE)
-26.0%Ovid Therapeutics Inc. lost 26.0% of its shareholders' money over the last year, higher than 63% of Healthcare companies in United States.
Owes vs Owns
0.10×Ovid Therapeutics Inc. owes $0.10 for every $1 it owns (low), lower than 87% of Healthcare companies in United States.
Dividend yield
NoneOvid Therapeutics Inc. does not currently pay a dividend.
Revenue growth
+1181%Revenue rose 1181% in the year to Dec 2025, and grew 69% a year on average over 3 years.
Profit growth
LossOvid Therapeutics Inc. made a loss in each of the last two years.
Profit margin
-240.1%Ovid Therapeutics Inc. lost $240 for every $100 of revenue.
Cash vs debt
Net cashOvid Therapeutics Inc. held $56 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Ovid Therapeutics Inc.: $463 M ÷ $210 M (30 Jun 2026) = 2.2.
What is Ovid Therapeutics Inc.'s return on equity?
Ovid Therapeutics Inc. lost 26.0% of its shareholders' money over the last year, higher than 63% of Healthcare companies in United States.
How much does Ovid Therapeutics Inc. owe compared with what it owns?
Ovid Therapeutics Inc. owes $0.10 for every $1 it owns (low), lower than 87% of Healthcare companies in United States.
Does Ovid Therapeutics Inc. pay a dividend?
No. Ovid Therapeutics Inc. does not currently pay a dividend.
Is Ovid Therapeutics Inc.'s revenue growing?
Revenue rose 1181% in the year to Dec 2025, and grew 69% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.